NLRP3 and type 2 diabetes mellitus: These findings suggest that OLT1177 reduces the “inflammatory metabolic cost” (i.e., excessive energy expenditure caused by chronic inflammation) through NLRP3 pathway inhibition, offering a novel therapeutic strategy for NLRP3-driven metabolic-inflammatory comorbidities, such as gout and type 2 diabetes (172).